Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Abstract Background The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed. Methods Postmenopausal women with untreated stage I–III HR+/HER2-ne...

Full description

Bibliographic Details
Main Authors: Barbara Adamo, Meritxell Bellet, Laia Paré, Tomás Pascual, Maria Vidal, José A. Pérez Fidalgo, Salvador Blanch, Noelia Martinez, Laura Murillo, Patricia Gómez-Pardo, Ana López-González, Kepa Amillano, Jordi Canes, Patricia Galván, Blanca González-Farré, Xavier González, Patricia Villagrasa, Eva Ciruelos, Aleix Prat
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Breast Cancer Research
Subjects:
Breast cancer
Metronomic
Vinorelbine
Letrozole
Window of opportunity
Gene expression
Online Access:http://link.springer.com/article/10.1186/s13058-019-1195-z

Internet

http://link.springer.com/article/10.1186/s13058-019-1195-z

Similar Items